115 related articles for article (PubMed ID: 32763783)
1. Survival outcomes of patients with advanced mucosal melanoma diagnosed from 2013 to 2017 in the Netherlands - A nationwide population-based study.
van Zeijl MCT; Boer FL; van Poelgeest MIE; van den Eertwegh AJM; Wouters MWJM; de Wreede LC; Aarts MJB; van den Berkmortel FWPJ; de Groot JWB; Hospers GAP; Piersma D; van Rijn RS; Suijkerbuijk KPM; Ten Tije AJ; van der Veldt AAM; Vreugdenhil G; Boers-Sonderen MJ; Kapiteijn EHW; Haanen JBAG
Eur J Cancer; 2020 Sep; 137():127-135. PubMed ID: 32763783
[TBL] [Abstract][Full Text] [Related]
2. Real-world Outcomes of First-line Anti-PD-1 Therapy for Advanced Melanoma: A Nationwide Population-based Study.
van Zeijl MCT; Haanen JBAG; Wouters MWJM; de Wreede LC; Jochems A; Aarts MJB; van den Berkmortel FWPJ; de Groot JWB; Hospers GAP; Kapiteijn EW; Piersma D; van Rijn RS; Suijkerbuijk KPM; Ten Tije AJ; van der Veldt AAM; Vreugdenhil G; van der Hoeven KJM; van den Eertwegh AJM
J Immunother; 2020 Oct; 43(8):256-264. PubMed ID: 32804914
[TBL] [Abstract][Full Text] [Related]
3. Survival outcomes of patients with advanced melanoma from 2013 to 2017: Results of a nationwide population-based registry.
van Zeijl MCT; de Wreede LC; van den Eertwegh AJM; Wouters MWJM; Jochems A; Schouwenburg MG; Aarts MJB; van Akkooi ACJ; van den Berkmortel FWPJ; de Groot JWB; Hospers GAP; Kapiteijn E; Piersma D; van Rijn RS; Suijkerbuijk KPM; Ten Tije AJ; van der Veldt AAM; Vreugdenhil G; van der Hoeven JJM; Haanen JBAG
Eur J Cancer; 2021 Feb; 144():242-251. PubMed ID: 33373869
[TBL] [Abstract][Full Text] [Related]
4. Trends in Incidence and Survival of 1496 Patients with Mucosal Melanoma in The Netherlands (1990-2019).
Boer FL; Ho VKY; Louwman MWJ; Schrader AMR; Zuur CL; Blank CU; van Poelgeest MIE; Kapiteijn EHW
Cancers (Basel); 2023 Feb; 15(5):. PubMed ID: 36900332
[TBL] [Abstract][Full Text] [Related]
5. Real-world outcomes of advanced melanoma patients not represented in phase III trials.
van Zeijl MCT; Ismail RK; de Wreede LC; van den Eertwegh AJM; de Boer A; van Dartel M; Hilarius DL; Aarts MJB; van den Berkmortel FWPJ; Boers-Sonderen MJ; de Groot JB; Hospers GAP; Kapiteijn E; Piersma D; van Rijn RS; Suijkerbuijk KPM; Ten Tije AJ; van der Veldt AAM; Vreugdenhil G; Haanen JBAG; Wouters MWJM
Int J Cancer; 2020 Dec; 147(12):3461-3470. PubMed ID: 32559817
[TBL] [Abstract][Full Text] [Related]
6. A study of the clinical characteristics and prognosis of advanced mucosal and cutaneous melanoma in a Chinese population.
Zhang Y; Fu X; Qi Y; Gao Q
Immunotherapy; 2019 Feb; 11(2):91-99. PubMed ID: 30511592
[TBL] [Abstract][Full Text] [Related]
7. Prognostic factors and disease-specific survival among immigrants diagnosed with cutaneous malignant melanoma in Sweden.
Simberg-Danell C; Lyth J; Månsson-Brahme E; Frohm-Nilsson M; Carstensen J; Hansson J; Eriksson H
Int J Cancer; 2016 Aug; 139(3):543-53. PubMed ID: 27004457
[TBL] [Abstract][Full Text] [Related]
8. Treatment of melanoma of unknown primary in the era of immunotherapy and targeted therapy: A Dutch population-based study.
Verver D; van der Veldt A; van Akkooi A; Verhoef C; Grünhagen DJ; Louwman WJ
Int J Cancer; 2020 Jan; 146(1):26-34. PubMed ID: 30801710
[TBL] [Abstract][Full Text] [Related]
9. Modeled Prognostic Subgroups for Survival and Treatment Outcomes in BRAF V600-Mutated Metastatic Melanoma: Pooled Analysis of 4 Randomized Clinical Trials.
Hauschild A; Larkin J; Ribas A; Dréno B; Flaherty KT; Ascierto PA; Lewis KD; McKenna E; Zhu Q; Mun Y; McArthur GA
JAMA Oncol; 2018 Oct; 4(10):1382-1388. PubMed ID: 30073321
[TBL] [Abstract][Full Text] [Related]
10. Prognostic score for patients with advanced melanoma treated with ipilimumab.
Diem S; Kasenda B; Martin-Liberal J; Lee A; Chauhan D; Gore M; Larkin J
Eur J Cancer; 2015 Dec; 51(18):2785-91. PubMed ID: 26597444
[TBL] [Abstract][Full Text] [Related]
11. The combination of stereotactic radiosurgery with immune checkpoint inhibition or targeted therapy in melanoma patients with brain metastases: a retrospective study.
Martins F; Schiappacasse L; Levivier M; Tuleasca C; Cuendet MA; Aedo-Lopez V; Gautron Moura B; Homicsko K; Bettini A; Berthod G; Gérard CL; Wicky A; Bourhis J; Michielin O
J Neurooncol; 2020 Jan; 146(1):181-193. PubMed ID: 31836957
[TBL] [Abstract][Full Text] [Related]
12. Metastatic melanoma: prognostic factors and survival in patients with brain metastases.
Frinton E; Tong D; Tan J; Read G; Kumar V; Kennedy S; Lim C; Board RE
J Neurooncol; 2017 Dec; 135(3):507-512. PubMed ID: 28819707
[TBL] [Abstract][Full Text] [Related]
13. Clinical characteristics and prognostic indicators for metastatic melanoma: data from 446 patients in north China.
Hao M; Zhao G; Du X; Yang Y; Yang J
Tumour Biol; 2016 Aug; 37(8):10339-48. PubMed ID: 26846098
[TBL] [Abstract][Full Text] [Related]
14. Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab.
Capone M; Giannarelli D; Mallardo D; Madonna G; Festino L; Grimaldi AM; Vanella V; Simeone E; Paone M; Palmieri G; Cavalcanti E; Caracò C; Ascierto PA
J Immunother Cancer; 2018 Jul; 6(1):74. PubMed ID: 30012216
[TBL] [Abstract][Full Text] [Related]
15. Real-world survival of patients with advanced BRAF V600 mutated melanoma treated with front-line BRAF/MEK inhibitors, anti-PD-1 antibodies, or nivolumab/ipilimumab.
Moser JC; Chen D; Hu-Lieskovan S; Grossmann KF; Patel S; Colonna SV; Ying J; Hyngstrom JR
Cancer Med; 2019 Dec; 8(18):7637-7643. PubMed ID: 31677253
[TBL] [Abstract][Full Text] [Related]
16. Prognostic factors for overall survival after radiosurgery for brain metastases from melanoma.
Marcus DM; Lowe M; Khan MK; Lawson DH; Crocker IR; Shelton JW; Melton A; Maynard N; Delman KA; Carlson GW; Rizzo M
Am J Clin Oncol; 2014 Dec; 37(6):580-4. PubMed ID: 23428955
[TBL] [Abstract][Full Text] [Related]
17. Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRCI) ocular melanoma study.
Khoja L; Atenafu EG; Suciu S; Leyvraz S; Sato T; Marshall E; Keilholz U; Zimmer L; Patel SP; Piperno-Neumann S; Piulats J; Kivelä TT; Pfoehler C; Bhatia S; Huppert P; Van Iersel LBJ; De Vries IJM; Penel N; Vogl T; Cheng T; Fiorentini G; Mouriaux F; Tarhini A; Patel PM; Carvajal R; Joshua AM
Ann Oncol; 2019 Aug; 30(8):1370-1380. PubMed ID: 31150059
[TBL] [Abstract][Full Text] [Related]
18. Improving survival in advanced melanoma patients: a trend analysis from 2013 to 2021.
van Not OJ; van den Eertwegh AJM; Haanen JB; Blank CU; Aarts MJB; van Breeschoten J; van den Berkmortel FWPJ; de Groot JB; Hospers GAP; Ismail RK; Kapiteijn E; Bloem M; De Meza MM; Piersma D; van Rijn RS; Stevense-den Boer MAM; van der Veldt AAM; Vreugdenhil G; Boers-Sonderen MJ; Blokx WAM; Wouters MWJM; Suijkerbuijk KPM
EClinicalMedicine; 2024 Mar; 69():102485. PubMed ID: 38370537
[TBL] [Abstract][Full Text] [Related]
19. Retrospective multicenter evaluation of patients diagnosed with mucosal melanoma: a study of Anatolian Society of Medical Oncology.
Ercelep O; Topcu TO; Bayoglu IV; Ekinci AS; Koca S; Kavgaci H; Ozcelik M; Alacacioglu A; Uzunoglu S; Bozkurt O; Ulas A; Aksoy A; Taskoylu BY; Gumussay O; Yaman S; Uysal M; Aydin D; Gumus M
Tumour Biol; 2016 Sep; 37(9):12033-12038. PubMed ID: 27173124
[TBL] [Abstract][Full Text] [Related]
20. Prognostic factors for first-line therapy and overall survival of metastatic uveal melanoma: The Princess Margaret Cancer Centre experience.
Nicholas MN; Khoja L; Atenafu EG; Hogg D; Quirt I; Butler M; Joshua AM
Melanoma Res; 2018 Dec; 28(6):571-577. PubMed ID: 30067547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
